statistiche ricercatore

statistiche per De Luca, Andrea

Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4595
NA - Nord America 2485
AS - Asia 1368
AF - Africa 15
Continente sconosciuto - Info sul continente non disponibili 3
SA - Sud America 3
OC - Oceania 1
Totale 8470
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2447
DE - Germania 1661
CN - Cina 1108
UA - Ucraina 881
PL - Polonia 664
FR - Francia 574
IT - Italia 355
FI - Finlandia 204
GB - Regno Unito 168
IN - India 134
TR - Turchia 81
SE - Svezia 36
CA - Canada 23
RU - Federazione Russa 20
JP - Giappone 19
NL - Olanda 13
CM - Camerun 8
MX - Messico 8
BZ - Belize 7
KR - Corea 6
CH - Svizzera 5
IR - Iran 5
VN - Vietnam 5
HK - Hong Kong 4
EU - Europa 3
IE - Irlanda 3
RO - Romania 3
BR - Brasile 2
ES - Italia 2
KE - Kenya 2
PH - Filippine 2
TW - Taiwan 2
UG - Uganda 2
BY - Bielorussia 1
CZ - Repubblica Ceca 1
IS - Islanda 1
LK - Sri Lanka 1
LT - Lituania 1
MA - Marocco 1
MK - Macedonia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PE - Perù 1
PT - Portogallo 1
SG - Singapore 1
ZA - Sudafrica 1
Totale 8470
Salva come PNG Salva come JPEG
Città #
Jacksonville 569
Kraków 520
Dearborn 287
Nanjing 275
Houston 153
Beijing 152
Cattolica 150
Warsaw 142
Redmond 138
Hangzhou 135
Woodbridge 129
Ashburn 110
Ann Arbor 106
Nürnberg 106
Nanchang 102
Seattle 90
Redwood City 86
Izmir 78
Lancaster 73
University Park 64
Shenyang 58
Mountain View 55
Milan 50
Kunming 48
Hebei 43
Changsha 39
Wilmington 39
Guangzhou 36
Fremont 34
Jiaxing 33
San Mateo 33
Fairfield 32
Munich 28
Tianjin 28
Jinan 27
Cambridge 19
Scottsdale 19
Shanghai 19
Simi Valley 19
Zhengzhou 18
Hefei 17
San Jose 17
Chicago 16
Rome 16
Ottawa 14
Detroit 12
Augusta 10
Changchun 8
Fuzhou 8
Wenzhou 8
Albuquerque 7
Auburn Hills 7
Belize City 7
Lanzhou 7
Leawood 7
Norwalk 7
Philadelphia 7
Las Vegas 6
Saarbrücken 6
Central District 4
Chongqing 4
Costa Mesa 4
Hanoi 4
Montréal 4
Ningbo 4
Baotou 3
Capelle 3
Cuauhtémoc 3
Mcallen 3
Napoli 3
New York 3
Phoenix 3
Siena 3
Southend 3
Taizhou 3
Toronto 3
Wuhan 3
Ardabil 2
Barcelona 2
Buffalo 2
Cameri 2
Chapar 2
Chengdu 2
Fabriano 2
Henderson 2
Kocaeli 2
Latina 2
Lequile 2
Los Angeles 2
New Delhi 2
Palermo 2
Pomezia 2
Ponte Buggianese 2
Quezon City 2
Quzhou 2
Stalettì 2
Valganna 2
Vittuone 2
Amsterdam 1
Aprilia 1
Totale 4433
Salva come PNG Salva come JPEG
Nome #
Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR. 273
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. 230
Common genetic variation and the control of HIV-1 in humans. 183
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 160
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 145
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 128
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 119
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 118
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 113
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 102
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 102
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 92
Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study 89
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 89
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 80
Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure 78
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 77
Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto SCTsuccessfully treated with combination treatment. 72
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study 72
Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. 69
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 67
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy 66
Highly active antiretroviral therapy and allogeneic CD34(+) peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia 64
Helicobacter pylori infection affects eosinophilic cationic protein in the gastric juice of patients with idiopathic chronic urticaria 64
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 62
Routine use of PCR-reverse cross-blot hybridization assay for rapid identification of Mycobacterium species growing in liquid media 61
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. 60
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 58
Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity? 57
Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar year: a cohort study 56
Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study 56
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 56
Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis 55
Declining tuberculosis and drug resistance rate among HIV-positive patients at an Italian teaching hospital in the era of highly active antiretroviral therapy 55
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 55
Evolution and predictors of HIV type 1 drug resistance in patients failing combination antiretroviral therapy in Italy 54
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop 54
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure 54
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 54
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 54
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 54
Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1 53
Serological response to hepatitis B virus vaccine in HIV-infected children in Tanzania 52
Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure. 51
Hyperbilirubinemia during atazanavir treatment in 2404 patients in the Italian atazanavir expanded access program and MASTER Cohorts 51
Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. 51
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons 51
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort 51
Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction? 50
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. 49
null 49
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 49
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 48
Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe 48
Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome--associated progressive multifocal leukoencephalopathy. 47
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study 47
Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine 46
Incidence and Predictors of Death, Retention, and Switch to Second-Line Regimens in Antiretroviral-Treated Patients in Sub-Saharan African Sites with Comprehensive Monitoring Availability 45
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 45
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 45
An outbreak of HIV-1 subtype G among Italian injecting drug users 44
Lipid-lowering effect of tenofovir in HIV-infected patients 44
Long term follow-up of Nevirapine-treated patients in a single centre cohort 43
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients 43
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 43
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 43
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 43
Interpretation systems for genotypic drug resistance of HIV-1 42
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 42
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 42
Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. 41
Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: two years experience in routine clinical practice 41
Prevalence of transmitted HIV-1 drug resistance in HIV-1 infected patients in Italy: evolution over 12 years and predictors 41
Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study 41
Key questions in antiretroviral therapy: Italian Consensus Workshop (2005). 40
Evolution of antiretroviral prescription and response over a period of 8 years: an Italian multicentre observational prospective cohort study 40
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 40
Clinical implications of HIV-1 drug resistance in the neurological compartment 40
Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response 40
Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals 40
Decline of CD4 T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals 39
Phemphigus vulgaris in a human-immunodeficiency-virus-infected patient. 39
Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. 38
The threshold bootstrap clustering: a new approach to find families or transmission clusters within molecular quasispecies 38
A novel methodology for large-scale phylogeny partition 38
Routine use of PCR-reverse cross-blot hybridization assay for rapid identification of Mycobacterium species growing in liquid media 38
Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation. 37
Risk of developing specific AIDS-defining illnesses in patients coinefcted with HIV and hepatitis C virus with or without liver cirrhosis 37
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 37
Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries 37
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group 36
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 36
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 36
Italian consensus statement on management of HIV-infected individualswith advanced disease naive to antiretroviral therapy 35
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 35
Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting 35
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 35
A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen 34
Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls 34
Impairment of recent thymic emigrants in HCV infection. 33
Totale 6095
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8603
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8603
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2016/20171300 2148819780 12398 4478 735619554
2017/20181441 604595409 12559 71176 14231122106
2018/20191360 486841166 252206 19142 447215179
2019/20202285 45823312287 183291 15294 116132188229
2020/20211750 13420745199 21599 19131 2723828039
2021/2022184 184000 00 00 0000
Totale 8603
 
 
 
Powered by IRIS-about IRIS-Utilizzo dei cookie
Logo CINECA  Copyright © 2021